There is currently no easy way to diagnose celiac disease in patients already following a gluten-free diet. In order for celiac disease blood tests to be accurate, patients on a gluten-free diet must undergo a “gluten challenge,” a temporary re-introduction of gluten into the diet, by consuming two slices of wheat-based bread daily for 6-8 weeks. A new study led by Dr. Robert P. Anderson found that a single-dose gluten challenge combined with an interleukin-2 assessment (a chemical in the body that modifies the immune system) may be a helpful tool in diagnosing and monitoring celiac disease for patients already on a gluten-free diet. A test that only requires one dose of gluten to detect celiac disease could make diagnosis much simpler.
Elevated serum interleukin-2 levels were found to correlate with the timing and severity of symptoms after a single-dose gluten challenge in patients with celiac disease. For this study, 25 celiac disease patients on a gluten-free diet and 25 healthy volunteers consumed 6 grams of gluten (equivalent to roughly 3 slices of wheat-based bread) for a gluten challenge. Symptom severity following the single-dose gluten challenge was self-reported by each participant. Symptoms were monitored up to 14 days after the gluten challenge for celiac disease patients and up to 24 hours in healthy volunteers. Serum interleukin-2 was measured before the gluten challenge, and then at 2, 4, and 6 hours after the gluten challenge.
Healthy control subjects showed no detectable levels of serum interleukin-2, while 92% of celiac patients showed no detectable levels at baseline, but levels greater than 0.5 pg/ml at 4 hours after gluten challenge. Patient-reported symptom severity remained steady for all healthy control subjects, while scores for celiac patients increased sharply after consuming gluten. The highest interleukin-2 levels correlated with the most severe symptoms, particularly nausea and vomiting.
A standardized gluten challenge and interleukin-2 measurement could be a valuable test to monitor and diagnose celiac disease in patients already on a gluten-free diet. A new diagnostic method requiring only a single dose of gluten may be especially useful for patients on a gluten-free diet who are unwilling, or unable, to maintain regular gluten consumption for the amount of time that a traditional gluten challenge requires (6-8 weeks). An easier, less painful diagnostic test such as this has the potential to increase rates of diagnosis among celiac patients and give researchers a more accurate picture of the celiac disease population.
Want to participate in a celiac disease clinical trial or study? Visit our Participate in Research page and our Clinical Trial Finder.
Stay informed. Click here to get updates on the latest developments in research news, advocacy, events, and more from the Celiac Disease Foundation.